Last updated: 2026-09-06 18:53:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GridAI Technologies Corp. (GRDX) operates in the ELECTRIC & OTHER SERVICES COMBINED sector and is listed on NASDAQ. The stock is currently priced at $3,27, with a market capitalization of $24,67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,87 to $6,93. This page covers its latest market performance, valuation, price trends and company information.
$24,67M | |
$3,20 | |
$6,93 | |
$1,87 | |
$2,97 | |
78,45K | |
-- | |
-- | |
$6,93 | |
$1,87 | |
-- | |
-- |
GridAI Technologies Corp. (GRDX) last closed at $2,97 as of 2026-09-04 23:31:00, unchanged from the previous close of $2,97.
During the latest regular trading session, GRDX traded between $1,87 and $6,93, with a volume of 78,45K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, GridAI Technologies Corp. (GRDX) moved from $3,83 to $3,27, representing a decline of 14,75% ($0,57).
The stock traded between $3,10 and $3,43 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 115,97 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 27,6%
GRDX is currently trading at $3,27, placing it 27,6% of the way from its 52-week low of $1,87 to its 52-week high of $6,93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
| Industry | ELECTRIC & OTHER SERVICES COMBINED |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GridAI Technologies Corp. (GRDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.